Dr. Carl D. Morrison joined the faculty of Roswell Park Comprehensive Cancer Center in January 2007, and is currently the Senior Vice President of Scientific Development and Integrative Medicine; Director of the Pathology Resource Network; Clinical Chief, Department of Pathology & Laboratory Medicine; Director, Division of Molecular Pathology, and Professor of Oncology. Prior to coming to Roswell Park, Dr, Morrison spent five years as faculty at The Ohio State University Medical Center after completing his residency there in Anatomic Pathology. Dr. Morrison is a board-certified pathologist with a Certificate of Qualification in Oncology in NYS who has an interest in both clinical and research areas.
As Senior Vice President of Scientific Development and Integrative Medicine, Dr. Morrison supports the development of new core capabilities and technology platforms in order to conduct highly integrative research across both the basic sciences and clinical care. Dr. Morrison continues to lead the Pathology Resource Network (PRN) at Roswell Park. The overall goal of the PRN is to facilitate access to human biospecimens for IRB-approved investigators with an emphasis on translational efforts. The services offered are quite diverse and serve a unique link between the research and clinical arena. Dr. Morrison started and previously directed the Clinical Data Network (CDN) at Roswell Park. The CDN is the organization of clinical data for research purposes utilizing a federated database approach. The primary goal of the CDN is the promotion of translational research at Roswell Park in a non-human subject research setting.
Dr. Morrison has over 100 publications regarding molecular technology that are examples of his understanding of the needs of cutting-edge technologies in both a research and clinical setting. The productivity and impact of Dr. Morrison’s published work is consistent with an h-index of 28, which is based on the set of the author’s most cited papers and the number of citations that they have received in other publications. While Dr. Morrison has studied and published in many areas of oncology, his most significant findings have been in the area of bone and soft tissue tumors where he described the first recurrent genetic changes in giant cell tumors of bone and chondrosarcomas. Through his research efforts Dr. Morrison has participated as PI or Co-PI for more than 30 grants, many of which were or are funded by the NCI. Complementing Dr. Morrison’s research interests is his clinical involvement as Director Molecular Pathology. In this role he designs, validates and signs out molecular pathology tests that impact patient care on a daily basis.
On a national basis Dr. Morrison is a previous Member of the Molecular Oncology Committee, College of American Pathologists, and is responsible for designing all proficiency testing for in-situ hybridization for all clinical laboratories in the United States. He served as founding member of the Department of Defense (DOD) Lung Integration Panel and currently functions as a member of the External Advisory Board for DOD Lung Cancer Biospecimen Resource Network. More recently, Dr. Morrison is deeply involved in the largest-ever initiative at the National Cancer Institute, The Cancer Genome Atlas (TCGA). Each TCGA is a comprehensive genomic characterization and analysis of the 20 most common cancers. As studies are published through TCGA’s network, the results are freely available to and widely used by the cancer community through the TCGA Data Portal.
Cancer Genome Atlas Research Network (Affiliated author). Comprehensive molecular portraits of human breast tumours. Nature. 2012 Sep 23. doi: 10.1038/nature11412. [Epub ahead of print]
Cancer Genome Atlas Research Network (Affiliated author). Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, Zhu Q, Omilian AR, Li X, Zhang J. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle. 2012 Aug 1;11(15):2922-30. Epub 2012 Aug 1.
Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One. 2012;7(6):e38783. Epub 2012 Jun 28.
Liu P, Morrison C, Wang L, Xiong D, Vedell P, Cui P, Hua X, Ding F, Lu Y, James M, Ebben JD, Xu H, Adjei AA, Head K, Andrae JW, Tschannen MR, Jacob H, Pan J, Zhang Q, Van den Bergh F, Xiao H, Lo KC, Patel J, Richmond T, Watt MA, Albert T, Selzer R, Anderson M, Wang J, Wang Y, Starnes S, Yang P, You M. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis. 2012 Jul;33(7):1270-6. Epub 2012 Apr 17.
Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jäger E. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802.
Cancer Genome Atlas Research Network (Affiliated author). Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609-15.
Morrison C, Radmacher M, Mohammed N, Suster D, Auer H, Jones S, Riggenbach J, Kelbick N, Bos G, Mayerson J. MYC Amplification and Polysomy 8 in Chondrosarcoma: Array CGH, FISH, and Association with Outcome. J Clin Oncol. 2005 Dec 20;23(36):9369-76.
Smith LT, Mayerson J, Nowak NJ, Suster D, Nehad Mohammed N, Long S, Auer HA, Jones S, McKeegan C, Young G, Bos G, Plass C, Morrison C. 20q11.1 Amplification in Giant Cell Tumor of Bone: Array CGH, FISH, and Association with Outcome. Genes Chromosomes Cancer. 2006 Oct;45(10):957-66.
Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.J Clin Oncol. 2008 20;26:848-55.